Table 2.
Surgical sample PDX by clinical molecular subtype
| Clinical molecular subtype | Total implanted | Any tumor growth | Verified breast tumor (%) |
|---|---|---|---|
| ER-/HER2+ | 3 | 1 | 1 (33.3) |
| ER+/HER2+ | 5 | 0 | 0 (0.0) |
| LumA | 3 | 0 | 0 (0.0) |
| LumB | 18 | 2 | 0 (0.0) |
| LumUnk | 1 | 0 | 0 (0.0) |
| Triple negative | 9 | 4b | 5 (55.6) |
| Totals | 35a | 7 | 6 (17.1) |
Abbreviations: PDX patient-derived xenograft, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, LumA luminal A, LumB luminal B, LumUnk luminal unknown
aAn additional two tumors were implanted and had growth but were not available for pathological confirmation
bOne triple negative PDX did not grow to the defined growth threshold due to mouse health condition, but did passage with verification